3 FDA label tables · Checked
3 tables on this site list low blood sugar. Each one is below, next to its own placebo group.
Each dot is 1 in 100 people.
Reported it Rest of a dose range Did not report it
Filled dots show the low end of a range. Dots are rounded. The exact number is above each grid.
SaxendaFDA-approved product
Row in the source: Low blood sugar (only people with type 2 diabetes were counted)
SaxendaFDA-approved product
Row in the source: Low blood sugar with symptoms
WegovyFDA-approved product
Row in the source: Low blood sugar (only people with type 2 diabetes were counted)
These lines are copied from our side effect pages, word for word.
Low blood sugar was more likely when liraglutide was taken with insulin or a diabetes medicine called a sulfonylurea.
In a Saxenda trial in adults with type 2 diabetes, 3 of 422 people on Saxenda (0.7%) needed another person's help for low blood sugar. All 3 were taking a sulfonylurea. No one on placebo did. In the Victoza trials, 8 people on Victoza had low blood sugar that needed another person's help. 7 of them were taking a sulfonylurea.
From Saxenda prescribing information on DailyMed and Victoza prescribing information on DailyMed .
Low blood sugar was more likely when semaglutide was taken with insulin or a diabetes medicine called a sulfonylurea.
One Ozempic trial added it to long-acting insulin. There, 0% to 1.5% of the Ozempic groups needed another person's help for low blood sugar. No one on placebo did. When Ozempic was taken with a sulfonylurea, 0.8% to 1.2% had this kind of low blood sugar.
From Ozempic prescribing information on DailyMed and Wegovy prescribing information on DailyMed .
When Mounjaro was taken alone, no one in the Mounjaro groups had a blood sugar below 54 mg/dL. On placebo, 1% did.
When Mounjaro was added to long-acting insulin, 14% to 19% of the Mounjaro groups had a blood sugar below 54 mg/dL, compared with 13% on placebo. 0% to 2% had low blood sugar that needed another person's help. No one on placebo did.
Low blood sugar was also more common when Mounjaro was taken with a diabetes medicine called a sulfonylurea.
In the Zepbound trial of adults with type 2 diabetes, 4.2% on Zepbound and 1.3% on placebo had a blood sugar below 54 mg/dL. Among people on Zepbound in that trial, it happened to 10.3% of those who also took a sulfonylurea and 2.1% of those who did not. In the trial of adults without diabetes, 0.3% on Zepbound and no one on placebo had a blood sugar below 54 mg/dL. That trial did not check for low blood sugar on a schedule, so this may undercount it. The Zepbound label says it can cause low blood sugar, including in adults without type 2 diabetes.
From Mounjaro prescribing information on DailyMed and Zepbound prescribing information on DailyMed .
Each bar is one set of trials. The dots on this page come only from the time inside each bar.
Stated length Range in the source Some people only
Saxenda, adults32 to 56 weeks, some up to about 3 years
Saxenda, teens56 weeks
Wegovy, adultsUp to 68 weeks
Trials can miss rare harms and harms that take years to appear.
Every number is copied from a table on our side effect pages. Those tables come from FDA labels on DailyMed, results posted on ClinicalTrials.gov, and company trial results. We did not add, total, or rank any number. Rows keep one fixed order: FDA-approved medicines first, then the rest, each in A to Z order.
We group rows by name. For example, “Tiredness (fatigue)” and “Tiredness or weakness (fatigue)” are both under tiredness. Each row still shows its own words from the source.
The tables on this site copy part of each label, such as the most common problems. A problem missing from one table may still have happened.
You can report a suspected side effect to the FDA at 1-800-FDA-1088 or through FDA MedWatch . If a reaction feels serious, get medical care first.